BioMedWire – Page 44 – InvestorBrandNetwork (IBN) Content Platform

How Can the Diagnosis and Treatment of Rare Diseases Be Improved?

July 8, 2020

July 8, 2020 08:35:13

Rare diseases have brought a more significant impact on the lives of several people more than AIDS and cancer combined, and statistics show that more than 450 million people are suffering from rare diseases worldwide. These rare diseases have escalated due to lack of education, shortage of improved technologies and infrastructure, which has made the diagnosis of these diseases so challenging. However, the good news is that steps are being taken to improve the diagnosis and treatment of rare diseases worldwide.

The Focus Should Be Changed from North America and Europe to the World

For the last 25 years since rare diseases emerged, little has been done to diagnose rare diseases. Focus has been on North America and Europe, thereby neglecting other countries. According to current data, 160,000-180,000 rare disease patients identified yearly came from Arabic countries and, at the same time, had autosomal recessive diseases. This scenario is attributed to the social norms that see a more significant frequency of same family marriages. Additionally, the family size in Arabic countries is also more significant than that of the two continents. Looking at the problem globally…

UK Company Secures Funds to Detect Epigenetic Cancer Signs

July 7, 2020

July 7, 2020 14:42:29

A University of Oxford spinout focusing on genomics will benefit from a seed round of $11.4 billion. It aims at improving cancer detection by measuring epigenetic changes to tumor DNA circulating in a patient’s blood. The oversubscribed seed funding round was pioneered by Oxford Sciences Innovation. It is a local early-stage investment enterprise connected to the University of Oxford.

Base Genomics will make use of technology developed at the University of Oxford called TAPS. TAPS is responsible for detecting epigenetic methylation of DNA at a single-base level. DNA methylation is a method in which cells can switch off specific genes without changing the DNA’s base code. DNA methylation can also be disrupted by different types of cancer. That way, physicians can find early signs…

BioMedNewsBreaks – InvestorBrandNetwork Announces Launch of Technology-Driven Communications Platform – BioMedWire

July 7, 2020

July 7, 2020 11:49:11

InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, today announced the launch of BioMedWire (“BMW”) as part of its sustained effort to provide specialized content distribution via widespread syndication channels. A laser-focused, technology-driven communications platform, BioMedWire is designed to provide the latest updates and information related to emerging market opportunities in the life sciences sector and beyond. “The life sciences sector has delivered incredible remedies and cures, saved and changed lives, and offered some of the greatest investment returns the markets have ever seen. The sector is constantly moving and evolving to meet the health and wellness challenges of the times, and BioMedWire is designed to keep investors abreast of developments and highlight companies in the sector that offer hope for improved quality of life,” Chris Johnson, director of client solutions for InvestorBrandNetwork, said in the news release. “By adding BioMedWire to our 45+ brands, we’re providing a powerful new platform for innovators in this space to speak directly to the investment community.”

To view the full press release, visit http://ibn.fm/jdumT

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 14+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information on IBN, visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Completes Acquisition of Quantitative Medicine LLC

July 7, 2020

July 7, 2020 09:55:14

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a biomedical analytics and computational biology company, in an all-stock transaction valued at approximately $1.8 million. Cofounded by Drs. Robert Murphy and Joshua Kangas, both of Carnegie Mellon University’s Computational Biology Department, QM developed its novel, computational drug-discovery platform CoRETM, an innovative machine learning platform that predicts the main effects of drugs on target molecules that mediate disease, which is expected to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs. “This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing,” Dr. Carl Schwartz, Predictive Oncology’s CEO, stated in the news release. “Integrating QM’s proven machine learning platform, CoRE, with our proprietary database of drug response and genomics profiles is expected to revolutionize the role of our AI-driven predictive models in the discovery and development of new anti-cancers. We will be able to more quickly understand how specific types of tumors react to cancer drug therapies. This will allow our customers to accelerate the development and commercialization of personalized patient treatments that dramatically improve patient outcomes. We intend to offer this new capability to our pharmaceutical company customers in revenue generating projects this year.”

To view the full press release, visit http://ibn.fm/i9Q4L

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology Inc. (NASDAQ: POAI) Announces Acquisition of Soluble Therapeutics, BioDtech as it Continues Buildout of Precision Medicine Business

July 6, 2020

July 6, 2020 12:51:40

Predictive Oncology announced the acquisition of Soluble Therapeutics Inc. & BioDtech Inc.
Acquired companies seek to enhance drug development process through the optimization of protein solubility and stability as well as through detection, removal of endotoxins
The companies were acquired for consideration amounting to 125,000 common shares and waiving of $1.07 million promissory note issued by parent company, InventaBioTech
Predictive Oncology seeks to build out its precision medicine business line, aimed at helping clinicians individualize cancer treatment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, announced that it had completed the acquisition of Soluble Therapeutics Inc. and BioDtech Inc. (http://ibn.fm/ccEdD). The company revealed that it had purchased the assets of Soluble and BioDtech, including certain intellectual property relating to contract research organization (“CRO”) services and equipment from parent company InventaBioTech for a total consideration of 125,000 shares of common stock. As part of the transaction, Predictive Oncology also waived all of the remaining amounts due and payable to the company under a secured promissory note of InventaBioTech in the principal amount of $1,070,000 relating to advances made by the company in 2017.

The acquisition of Soluble Therapeutics and BioDtech marks a new step in Predictive Oncology’s journey towards building out its precision medicine business, following its acquisition of its Helomics arm in April 2019. Soluble Therapeutics, which was founded in 2008 with the aim of commercializing technology licensed from…

Vivos Therapeutics, Inc. Launches Promising Treatment of Mild to Moderate Obstructive Sleep Apnea in Adults

June 24, 2020

June 24, 2020 12:34:54

Obstructive Sleep Apnea (“OSA”) impacts up to 1 billion people globally, including 54 million Americans
Estimates suggest OSA costs the U.S. economy $165 billion annually
Vivos System offers significant advantages over traditional OSA treatment approaches
Over 4,300 healthcare professionals registered for Vivos’ education and training Summit in March 2020, with strong and growing interest in this disruptive new technology

Vivos Therapeutics’ Vivos System is the first treatment modality for mild to moderate OSA based on the ability to remodel and enhance the function, size, and shape of the human airway, in most cases avoiding the need for lifelong interventions. The system’s treatment time is a fraction of that of its alternatives, potentially relieving symptoms in a matter of 18-24 months in most cases without the need for surgery (http://nnw.fm/7opjM).

The company’s existing mRNA (Mandibular Repositioning Appliance) is an FDA cleared class II device that treats mild to moderate sleep apnea, snoring, and sleep disordered breathing in adults. This is great news for people suffering from sleep apnea, as the device for most patients can serve as a potential lasting solution to these frustrating and dangerous conditions. It is estimated that OSA affects approximately…